Trial Profile
A Phase II Study of Osimertinib With On-study and Post-progression Biopsy in the First Line Treatment of EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 May 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 25 May 2023 Planned primary completion date changed from 1 Mar 2024 to 20 Aug 2024.
- 27 Mar 2023 Planned End Date changed from 1 Mar 2025 to 1 Mar 2026.
- 27 Mar 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Mar 2024.